Chembio Diagnostics, Inc. (CEMI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.93+0.84 (+13.79%)
As of 12:40 PM EDT. Market open.
People also watch:
CASMAHPIELMDCCXIAXGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open6.13
Prev Close6.09
Bid6.95 x 100
Ask6.99 x 700
Day's Range6.13 - 7.47
52wk Range3.51 - 9.40
1y Target EstN/A
Market Cap83.06M
P/E Ratio (ttm)-6.85
Beta1.43
Volume739,560
Avg Vol (3m)76,975
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 hours ago

    Chembio Awarded Up to $13.2 Million U.S. Government Contract to Develop and Commercialize Point-of-Care Tests for Zika Virus

    MEDFORD, N.Y., Aug. 25, 2016-- Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that it has been awarded a contract for up to $13.2 million ...

  • GlobeNewswire7 days ago

    Chembio Expands Product Distribution through Exclusive Agreement with Isla Lab in the Caribbean

    MEDFORD, N.Y., Aug. 18, 2016-- Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution ...

  • Zacks Small Cap Research9 days ago

    CEMI: Significant Growth Opportunity in Fever Accelerating Shift From STD

    In late July Chembio preannounced expected Q2 revenue of $3.2M - $3.3M.  Lower U.S. lateral flow sales and DPP sales to FIOCRUZ were cited as the reasons for the implied ~50% contraction from both the prior year period as well as from Q1 of this was  year.  Following the preannouncement we downwardly revised our $5.0M estimate to $3.3M, including $2.6M in product sales (from $4.2M) and $677k from license, R&D contracts and grants income (from $810k). Last week Chembio reported financial results for the second quarter ending June 30th.  While grant income was well ahead of our number ($1.2M A vs. $677k E) due to greater and earlier than anticipated recognition of a bulk of the Paul G. Allen fever panel grant, product sales came in about 21% shy ($2.0M A vs. $2.6m E) of our revised estimate.  The difference in actual and our revised product sales number is mostly concentrated in lower international lateral flow - which is not a particular concern given the great historical variability in this line item and the relationship to (hard to predict) international aid tenders.